A Phase 1 Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced anti-Tumor Immunity In Patients with NY-ESO-1 Expressing Solid Tumors
Description: 

The purpose of this study is to test the safety of a treatment called DC205 NY ESO 1 vaccine, given with and without sirolimus, and to see what effects (good or bad) it has on you and your type of cancer.

Study Number: 

I 191511

Phase: 
I
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01522820

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.